EyePoint Pharmaceuticals, Inc. (EYPT) P/E Ratio History
Historical price-to-earnings valuation from 2010 to 2015
Loading P/E history...
EYPT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) trades at a price-to-earnings ratio of -4.2x, with a stock price of $13.41 and trailing twelve-month earnings per share of $-2.79.
The current P/E is 131% below its 5-year average of 13.8x. Over the past five years, EYPT's P/E has ranged from a low of 7.8x to a high of 20.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, EYPT trades at a 119% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, EYPT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EYPT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EYPT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1Lowest | 2.70Best | +8%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
EYPT Historical P/E Data (2010–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q2 | $37.70 | $1.86 | 20.3x | +47% | |
| FY2015 Q1 | $39.50 | $2.25 | 17.6x | +28% | |
| FY2014 Q4 | Wed Dec 31 2014 00:00:00 GM | $41.10 | $3.16 | 13.0x | -6% |
| FY2014 Q3 | $44.20 | $3.25 | 13.6x | -1% | |
| FY2011 Q2 | $42.80 | $3.91 | 10.9x | -21% | |
| FY2011 Q1 | $39.20 | $2.52 | 15.6x | +13% | |
| FY2010 Q3 | $43.80 | $3.84 | 11.4x | -17% | |
| FY2010 Q2 | Wed Jun 30 2010 00:00:00 GM | $36.10 | $4.65 | 7.8x | -44% |
Average P/E for displayed period: 13.8x
See EYPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EYPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EYPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
Is EYPT stock overvalued or undervalued?
EYPT trades at -4.2x P/E, below its 5-year average of 13.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does EYPT's valuation compare to peers?
EyePoint Pharmaceuticals, Inc. P/E of -4.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is EYPT's PEG ratio?
EYPT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2010-2015.